Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy

Fig. 3

CN133 inhibit PCa growth in C56BL/6 J mice bearing murine RM1 subcutaneous tumors, mainly by downregulation of PMN-MDSC infiltration and function. A Flow cytometric analyses examined PMN-MDSC (CD11b + Ly-6G +) expression in the blood of subcutaneous PCa model in both of CN133 and placebo groups at day 25. B, C Flow cytometric analyses tested the expression of granzyme B and perforin (B), Arg-1, and iNOS (C) in the spleens of subcutaneous PCa model in the CN133 and placebo groups at day 25. D Representative fluorescent images of infiltration of PMN-MDSCs after day 25 of CN133 treatment or placebo treatment from the subcutaneous PCa tumor tissues; scale bar, 50 μm

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us